Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous s stock reports and market updates.
Forest Laboratories, Inc. (NYSE: FRX) shares gained 0.79 percent to close at $94.58 a share Wednesday. The stock traded between $92.97 and $95.00 on volume of 1.69 million shares traded. Analysts at Piper Jaffray have recently downgraded the company’s rating to “neutral” from “overweight”. Shares of Forest Laboratories have gained approximately 58.0 percent year-to-date.
Find out more about Forest Laboratories including full access to the free equity report at: www.RDInvesting.com/FRX
Intersil Corp. (NASDAQ: ISIL) shares gained 2.13 percent to close at $12.95 a share Wednesday. The stock traded between $12.69 and $13.01 on volume of 2.12 million shares traded. Analysts at Piper Jaffray have recently initiated coverage on the company with an “overweight” rating and a price target of $14.00. Shares of Intersil have gained approximately 13.0 percent year-to-date.
Find out more about Intersil including full access to the free equity report at: www.RDInvesting.com/ISIL
PharMerica Corporation (NYSE: PMC) shares gained 6.99 percent to close at $26.49 a share Wednesday. The stock traded between $25.21 and $26.51 on volume of 439,901 shares traded. Analysts at Credit Suisse have recently upgraded the company’s rating to “outperform” from “neutral”. Shares of PharMerica have gained approximately 23.0 percent year-to-date.
Find out more about PharMerica including full access to the free equity report at: www.RDInvesting.com/PMC
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) shares dropped 13.83 percent to close at $4.55 a share Wednesday. The stock traded between $4.34 and $4.70 on volume of 7.36 million shares traded. Analysts at BMO Capital Markets have recently downgraded the company’s rating to “underperform” from “market perform”. Shares of Synta Pharmaceuticals have fallen approximately 8.0 percent year-to-date.
Find out more about Synta Pharmaceuticals including full access to the free equity report at: www.RDInvesting.com/SNTA
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact: Research Driven Investing [email protected]